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Abstract
Purpose This study aimed to evaluate the feasibility and tol-
erability of biweekly docetaxel with capecitabine as first-line
treatment in advanced gastro-oesophageal cancer.
Methods Fifty-three patients at median age of 61 years with
advanced gastric cancer were included in this prospective,
non-randomized, multicentre phase II trial to receive intrave-
nous docetaxel 50 mg/m2 on days 1 and 15, and oral capecit-
abine 1250 mg/m2 every 12 h, on days 1–7 and 15–21 of each
28-day cycle. QOL was assessed using EORTC QLQ-C30,
together with the gastric module (QLQ-STO 22).
Results Forty-six patients were evaluable for QOL analyses.
No deterioration in global health status was found. Social
functioning scores improved, and eating difficulties and pain
were alleviated during treatment. The most common grade 3
or 4 toxicity was neutropenia (47%), whereas neutropenic
fever was uncommon (6%). The clinical benefit rate was
60%, including complete and partial responses as well as sta-
bilized disease. Median overall survival was 8.8 months (95%
CI 5.8–11.9 months), and median time to progression was
6.2 months (95% CI 4.9–7.5 months).
Conclusions Biweekly docetaxel with capecitabine is a feasi-
ble treatment in AGC, delivered on an outpatient basis, with
no need for central venous access device. No deterioration of
global health status was reported. In addition, pain and eating
difficulties were alleviated during study treatment. This trial is
registered at ClinicalTrials.gov, number NCT00669370.
Keywords Quality of life . Advanced gastro-oesophageal
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Introduction
The incidence of distal gastric cancer is decreasing, whereas
cancers of the distal oesophagus and gastro-oesophageal junc-
tion tend to increase in the Western world [1]. Worldwide,
these cancers cause substantial morbidity and mortality.
Nearly one million new cases and more than 700,000 deaths
due to gastric cancer were estimated to have occurred in 2012,
setting gastric cancer the fifth most common cancer and the
third most common cause of cancer death [2]. The prognosis
of advanced gastro-oesophageal cancer (AGC) remains poor
[1, 2]. A substantial proportion of patients presents with or
ends up having metastatic disease after initial treatment [3, 4].
Systemic chemotherapy is shown to improve disease out-
come in AGC, as compared to best supportive care, with me-
dian survival rates reaching 6–9months [5–7]. During the past
decade, several new-generation cytotoxic agents, including
capecitabine, irinotecan, oxaliplatin and docetaxel, have been
investigated in the treatment of metastatic gastric cancer
[7–10]. Two previous large phase III trials demonstrated an
oral fluoropyrimidine capecitabine not to be inferior to 5-FU
in the setting of a platinum-containing doublet or triplet for
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AGC [8, 9]. Adding docetaxel into the combination of cisplat-
in and fluorouracil (DCF) was studied in a randomized phase
III trial in first-line therapy for AGC. The final results showed
improved survival, response rate, and health-related QOL, al-
beit increased toxicity with DCF [10]. Further, in a phase III
open-label, randomized controlled trial in HER2-positive
AGC, trastuzumab in combination with chemotherapy signif-
icantly improved median overall survival as compared to che-
motherapy alone [11]. Recently, VEGFR-2 antagonist
ramucirumab was found to improve survival as monotherapy
or in combination with paclitaxel in AGC after first-line treat-
ment [12, 13]. However, so far, no survival benefit has been
reported in the first-line setting with other novel targeted
agents in AGC, in addition of trastuzumab.
In advanced cancer, the primary treatment goals are to pro-
long survival, relieve symptoms and sustain or improve the
quality of life. Thereby, chemotherapy-related toxicity is an
important issue when determining the true value of treatment.
Patients with AGC are generally elderly and exhibit poor gen-
eral performance status, which emphasizes the need for effec-
tive treatment options and improved control of side effects. On
the basis of these considerations, we conducted a phase II trial
to determine the feasibility and tolerability of biweekly doce-
taxel in combination with capecitabine as first-line treatment
of patients with AGC.
Patients and methods
Study design and patient population
This prospective, non-randomized, multicentre phase II trial
included patients over 18 years of age with histologically con-
firmed, locally advanced (inoperable) or metastatic adenocar-
cinoma of the stomach or gastro-oesophageal junction.
Disease lesions could be either evaluable or measurable. No
previous chemotherapy for advanced or metastatic disease
was allowed, and a time interval of ≥6 months after adjuvant
chemotherapy was imperative. Patients were required to have
adequate haematological (neutrophils >1.5 × 109/l,
haemoglobin ≥100 g/l after transfusion when needed and
platelets ≥100 × 109/l), renal (serum creatinine ≤1.25 × upper
normal limit) and liver function (total serum bilirubin ≤1.25 ×
upper normal limit or alanine aminotransferase ≤3 × upper
normal limit, alkaline phosphatase ≤2.5 × upper normal limit,
unless bone metastases; in case of liver metastasis total serum
bilirubin ≤1.5 × upper normal limit and alanine aminotrans-
ferase ≤5 × upper normal limit). Prophylactic use of granulo-
cyte colony-stimulating factor (G-CSF) was not allowed.
Exclusion criteria included pregnancy or breast feeding,
metastatic disease to the central nervous system, unresolved
bowel obstruction or dysmotility, chronic diarrhoea, clinically
significant malabsorption syndrome, inability to swallow
tablets, known dihydropyrimidine dehydrogenase deficiency,
peripheral neuropathy ≥grade 2, concurrent severe and/or un-
controlled co-morbid medical condition such as uncontrolled
infection, hypertension, ischemic heart disease, myocardial
infarction within previous 6 months or congestive heart dis-
ease. Patients with previous serious hypersensitive reactions,
history of allergy to drugs containing the excipient TWEEN
80® or 5-fluorouracil, major surgery within 4 weeks prior to
study treatment or passage disorder were also excluded from
the participation in the study.
Study treatment
Patients received intravenous docetaxel 50 mg/m2 on days 1
and 15 and oral capecitabine 1250 mg/m2 every 12 h, starting
on days 1 and 15 in the evening and continuing on days 2–7
and 16–21. One cycle consisted of 28 days. Premedication
with 7.5 mg of oral dexamethasone or methylprednisolone
40 mg was given the evening prior to docetaxel infusion and
continuing thereafter every 12 h three times. Dose reduction
was based on the most severe grade of toxicity in the previous
cycle. A planned cycle could be delayed up to 21 days due to
toxicity. If a patient had not recovered from toxicities within
21 days, he/she was withdrawn from the study. In case either
Table 1 Patient characteristics (n = 53)
Median age (range) (years) 61 (28–79)
Sex, n (%)
Male 36 (68)
Female 17 (32)
ECOG performance status, n (%)
0 10 (19)
1 39 (74)
2 4 (7)
Location of primary tumour, n (%)
Oesophagogastric junction 21 (40)
Gastric 32 (60)
Resection of primary tumour, n (%)
Yes 19 (36)
No 34 (64)
Previous adjuvant chemotherapy, n (%) 10 (19)
Previous radiotherapy, n (%) 8 (15)
Organ involvement, n (%)
Stomach 34 (64%)
Lymph nodes 25 (47%)
Liver 12 (33%)
Peritoneum 11 (21%)
Number of disease sites, n (%)
1 20 (38)
2 26 (49)
≥3 7 (13)
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of the test docetaxel or capecitabine was discontinued due to
an adverse event, the patient could continue in the study taking
only one test drug.
Efficacy and safety assessments
Before study inclusion, patients underwent complete physical
examination, blood analysis (haematology and biochemistry),
electrocardiogram and computerized tomography (CT) scan
of the abdomen and pelvis as well as CTof the thorax or chest
x-ray. Blood samples were taken for haematology tests prior
to each treatment on days 1 and 15 of each cycle.
Biochemistry tests were performed before the start of each
cycle. During treatment, imaging of target and non-target le-
sions was repeated every three cycles (every 12 weeks) or as
clinically indicated. Tumour response was classified accord-
ing to RECIST [14].Toxicity was evaluated before every cycle
using National Cancer Institute-Common Terminology
Criteria for Adverse Events [15].
Quality of life assessments
Quality of life (QOL) was assessed using European
Organization for Research and Treatment of Cancer Quality-
of-Life Questionnaire (EORTCQLQ-C30) [16], together with
the gastric module (QLQ-STO 22) [17]. QLQ assessment was
performed at baseline, on day 1 of the second and subsequent
cycles (prior to the infusion), at the end-of-study visit, during
follow-up until progression or the start of second-line treat-
ment or death. Prerequisites for inclusion in the analyses of (a
change in) physical functioning score consisted of at least one
given treatment cycle as well as QLQ-questionnaire filled at
baseline and after the first treatment cycle. The physical func-
tioning score was measured using the EORTC QLQ-C30 and
QLQ-STO 22 [16, 17].
Statistical analysis
The primary end point of the study was physical functioning
score, measured by the EORTC QLQ-C30 and QLQ-STO 22
instruments, comparing the scores received at baseline with
those obtained after one treatment cycle, using a paired t test.
Secondary end points were time to progression (TTP), overall
response rate (ORR) and overall survival (OS).
Summary measurements are presented as mean and stan-
dard deviation (SD) or as median with 25th–75th percentile,
unless otherwise stated. The change from baseline for contin-
uous variables was analysed by paired samples t test. The
Kaplan-Meier curve was created to show overall survival from
recruitment to the end of follow-up (i.e. death or end of the
study). All analyses were performed using SPSS for Windows
(IBM Corp. Released 2011. IBM SPSS Statistics for
Windows, version 20.0. Armonk, NY: IBM Corp.)
Table 2 The main results of QoL-C30 and STO-22 questionnaires
Variable Baseline n = 46 Cycle 1 n = 45 Cycle 2 n = 37 Cycle 3 n = 30 Cycle 4 n = 27 Cycle 5 n = 20
Global health status 62 (SD19) 64 (SD19) 67 (SD18) 66 (SD17) 62 (SD16) 62 (SD16)
p = 0.002 p = 0.018
Physical functioning 77 (SD18) 76 (SD17) 78 (SD17) 77 (SD16) 77 (SD17) 77 (SD18)
p = 0.012
Social functioning 83 (SD20) 82 (SD19) 84 (SD22) 87 (SD18) 91 (SD15) 87 (SD16)
p = 0.005
Emotional functioning 76 (SD20) 84 (SD17) 86 (SD14) 87 (SD12) 85 (SD20) 84 (SD17)
p = 0.004 p = 0.011 p = 0.004 p = 0.025
Cognitive functioning 87 (SD14) 89 (SD14) 90 (SD13) 86 (SD16) 88 (SD14) 89 (SD17)
Role functioning 68 (SD31) 74 (SD24) 79 (SD25) 80 (SD23) 80 (SD16) 77 (SD29)
Fatigue 33 (SD19) 32 (SD17) 31 (SD20) 30 (SD20) 30 (SD18) 28 (SD20)
Pain 26 (SD16) 20 (SD15) 15 (SD11) 14 (SD12) 13 (SD14) 1 (SD12)
p = 0.01 p < 0.001 p = 0.001 p = 0.001 p = 0.002
Eating restrictions 29 (SD23) 22 (SD20) 15 (SD17) 19 (SD18) 16 (SD19) 15 (SD12)
p = 0.001 p = 0.005
Dysphagia 31 (SD31) 26 (SD24) 21 (SD25) 20 (SD23) 18 (SD16) 22 (SD29)
Taste 16 (SD25) 27 (SD28) 37 (SD28) 36 (SD33) 30 (SD21) 38 (SD25)
p = 0.004 p < 0.001 p = 0.007 p = 0.003 p = 0.030
Anxiety 46 (SD23) 38 (SD21) 34 (SD19) 33 (SD31) 31 (SD21) 32 (SD18)
p = 0.001 p = 0.006 p = 0.001 p = 0.002 p = 0.011
The values are presented as mean with standard deviation (SD). The scores of each cycle as compared to the baseline score
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Results
Patients and treatment
This prospective phase II trial was conducted at four univer-
sity hospitals and one central hospital in Finland. A total of 53
patients were registered between June 2006 and December
2009. One patient was withdrawn from the study after the first
cycle due to detected HER2-positivity, necessitating the start
of trastuzumab treatment. Altogether, 46 patients were eligible
for the QOL analyses. The patient characteristics are summa-
rized in Table 1.
The total number of chemotherapy cycles administered
was 220. The median number of treatment cycles per patient
was 4 (range, 0.5–16), and the median time on study treatment
was 4.8 months (range, 0.1–17.6 months). The main reasons
for treatment discontinuation were progressive disease or de-
teriorating general condition (n = 31, 58%). Altogether, 26
patients (49%) received second-line chemotherapy.
Effect of treatment on quality of life
The number of patients with assessable QOL questionnaires at
baseline was 46 (45 for global health status and STO 22 ques-
tionnaires), after the first and subsequent four cycles, the num-
ber of patients was 45, 37, 30, 27 and 20, respectively.
Detailed results QOL analyses are shown in Table 2. Pain
and eating restrictions were common at baseline (Fig. 1a).
During treatment, clinically relevant alleviation was detected
both in pain and in eating restrictions. No deterioration in
global health status or in social or physical functioning oc-
curred (Fig. 1a–c).
Clinical benefit
One of the 53 patients (2%) achieved complete response (CR),
and 8 patients (15%) had partial response (PR). Of the pa-
tients, 23 (43%) showed stable disease (SD) and 5 (9%) had
progressive disease (PD). The clinical benefit rate was 60%.
The response was not evaluable among 18 patients (30%), due
to early discontinuation of the study treatment. Median time to
progression was 6.2 months (95% CI 4.9–7.5 months) and
median overall survival 8.8months (95%CI 5.8–11.9months)
(Fig. 2a, b).
Safety
During study treatment, 25 (47%) patients were hospi-
talized. Fifty percent of the hospitalizations were
caused by a treatment-related adverse event. The most
common grade 3 or 4 toxicity was neutropenia, detect-
ed in 25 patients (47%). However, only three patients
(6%) experienced neutropenic fever. One patient had a
grade 3 allergic reaction during docetaxel infusion, precluding
further treatment. There were no direct treatment-related
deaths. One sudden death occurred during the first treatment
cycle. According to the autopsy report, the cause of death was
metastatic gastric cancer and no evidence of cardiac-related
death could be detected. The common adverse events are listed
in Table 3.
0
20
40
60
80
100
M
e
a
n
Cycle
Global health status
n = 45 45 37 30 27 20
0
20
40
60
80
100
M
e
a
n
Cycle
 Social function
 Physical function
0
20
40
60
80
100
M
e
a
n
Cycle
 STO22 Pain
 STO22 Eating restriction
0 1 2 3 4 5
0 1 2 3 4 5
n = 46 45 37 30 27 20
0 1 2 3 4 5
n = 45 45 37 30 27 20
a
b
c
Fig. 1 Effect of treatment on quality of life: a global health status, b
social and physical function, and c pain and eating restrictions
presented as mean values per cycle
2774 Support Care Cancer (2017) 25:2771–2777
Discussion
This prospective phase II trial with a combination of biweekly
docetaxel and capecitabine in AGC showed no deterioration
of global health status or either physical or social functioning.
Importantly, the patients’ quality of life was not compromised
during treatment. Moreover, disease-associated symptoms, in-
cluding eating restrictions and dysphagia, as well as pain and
anxiety, were alleviated during study treatment. The regimen
was also conveniently delivered on an outpatient setting with-
out a need for central venous access device.
Docetaxel in various combinations has previously been
studied in the treatment in AGC, also including QOL assess-
ments [18–21]. A recent prostate cancer trial reported better
time to treatment failure and fewer serious adverse events with
two weekly than with three weekly dosing of docetaxel [22].
Fig. 2 aMedian time to
progression. bMedian overall
survival
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In AGC, docetaxel combined to cisplatin and fluorouracil re-
sulted in better symptom palliation and improved QOL, as
compared to treatment with epirubicin, cisplatin and fluoro-
uracil. Unfortunately, treatment toxicity data for this combina-
tion were not readily provided [19]. Previous trials have gen-
erally demonstrated improved QOL accompanied with im-
proved efficacy in AGC, despite increased toxicity with doce-
taxel triplet combinations [10, 18, 19, 21], i.e. treatment effi-
cacy rather than toxicity tends to affect QOL [23].
Importantly, in the current study, the patients’ QOL was not
compromised during treatment. Eating difficulties were alle-
viated during chemotherapy but started deteriorating along
with disease progression. Similarly, after commencing thera-
py, pain was experienced to relieve but intensify again as
cancer progressed. Physical functioning remained stable dur-
ing chemotherapy, while social functioning improved, even
despite disease progression. The global health status was
maintained or slightly improved during therapy.
Gubanski and colleagues investigated the effect of sequential
treatment on QOL. Patients were randomized to start treatment
with either docetaxel or irinotecan combined to fluorouracil and
leucovorin. After four cycles, the treatment was switched.
Chemotherapy was not found to affect the average QOL scores.
Instead, patients with a radiological response were able to sus-
tain better QOL as compared to patients with no radiological
response [24]. A patient’s perception of expected treatment effi-
cacy might also influence on QOL scores: a substantial
proportion of patients may not comprehend their disease unlike-
ly to be curable [25]. Thus, they may be ready to tolerate even
serious side effects and yet experience QOL to be maintained.
The results of this study showed the clinical benefit rate to be
60%, including complete (CR) and partial (PR) responses and
stabilized disease (SD), and median overall survival of
8.8 months. These findings are parallel to a previous trial of
weekly docetaxel together with capecitabine on days 1–14 of a
21-day cycle, showing a comparable response rate of 29%,
stable disease of 44% and overall survival reaching 10.7months
[26]. Another study investigating dose-dependent efficacy of
docetaxel and capecitabine resulted in improved overall re-
sponse rates with full dosing of these agents. However, two
patients in each cohort experienced grade 3–4 cardiac arrhyth-
mia, one patient pulmonary oedema, and three patients grade 3–
4 thrombosis/pulmonary embolism, one of them leading to
death [27]. In the current study, no death was directly associated
to study treatment. One patient died after the very first infusion
of chemotherapy due to rapidly progressing cancer, without any
signs of cardiac complications in the autopsy. However, ven-
tricular fibrillation cannot entirely be ruled out, despite of a
negative autopsy report. In the current study, only one patient
experienced grade 3–4 cardiac arrhythmia.
Our study shows a moderate incidence of grade 3–4 neutro-
penia, resulting only rarely in neutropenic fever. Nevertheless,
infection was the main reason for treatment-related hospitaliza-
tion. These results are comparable with earlier studies, reporting
even higher rates of grade 3–4 neutropenia, in up to 23–80% of
patients, febrile neutropenia among 2–12% and grade 3–4 non-
neutropenic fever among 2–41% of patients, while hospitaliza-
tion data are not readily available [19, 26, 27]. The incidence of
mild palmo-plantar dysesthesia or hand-foot syndrome (HFS)
was previously reported to be 9–42% and that of severe HFS 3–
20% [19, 26, 27]. Even though the incidence of HFS in the
current study was 45%, no grade 3–4 symptoms were detected.
Likewise, mild diarrhoea was frequent but severe diarrhoea a
rare event. On the whole, haematologic and non-haematologic
toxicities were considered tolerable.
In conclusion, no treatment combination has been proven
superior as compared to others in AGC in the palliative set-
ting. Biweekly docetaxel, together with capecitabine is a fea-
sible, outpatient-based, well-tolerated treatment that enables
sustaining QOL and alleviating disease-associated symptoms.
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